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ABSTRACT
Here, we show that new mitochondrial biogenesis is required for the anchorage 
independent survival and propagation of cancer stem-like cells (CSCs). More 
specifically, we used the drug XCT790 as an investigational tool, as it functions as a 
specific inhibitor of the ERRα-PGC1 signaling pathway, which governs mitochondrial 
biogenesis. Interestingly, our results directly demonstrate that XCT790 efficiently 
blocks both the survival and propagation of tumor initiating stem-like cells (TICs), 
using the MCF7 cell line as a model system. Mechanistically, we show that XCT790 
suppresses the activity of several independent signaling pathways that are normally 
required for the survival of CSCs, such as Sonic hedgehog, TGFβ-SMAD, STAT3, and 
Wnt signaling. We also show that XCT790 markedly reduces oxidative mitochondrial 
metabolism (OXPHOS) and that XCT790-mediated inhibition of CSC propagation can be 
prevented or reversed by Acetyl-L-Carnitine (ALCAR), a mitochondrial fuel. Consistent 
with our findings, over-expression of ERRα significantly enhances the efficiency of 
mammosphere formation, which can be blocked by treatment with mitochondrial 
inhibitors. Similarly, mammosphere formation augmented by FOXM1, a downstream 
target of Wnt/β-catenin signaling, can also be blocked by treatment with three 
different classes of mitochondrial inhibitors (XCT790, oligomycin A, or doxycycline). 
In this context, our unbiased proteomics analysis reveals that FOXM1 drives the 
expression of >90 protein targets associated with mitochondrial biogenesis, glycolysis, 
the EMT and protein synthesis in MCF7 cells, processes which are characteristic of an 
anabolic CSC phenotype. Finally, doxycycline is an FDA-approved antibiotic, which is 
very well-tolerated in patients. As such, doxycycline could be re-purposed clinically 
as a ‘safe’ mitochondrial inhibitor, to target FOXM1 and mitochondrial biogenesis in 
CSCs, to prevent tumor recurrence and distant metastasis, thereby avoiding patient 
relapse.
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INTRODUCTION
Tumor-initiating stem-like cells (TICs) are a small 
sub-population of tumor cells that are resistant to most 
anti-cancer therapies, including radio- and chemotherapy, 
and are able to expand and regenerate tumors, after 
conventional therapy is completed [1-4]. As such, TICs are 
responsible for tumor recurrence, metastatic dissemination, 
and, ultimately, patient death. As a consequence, TICs 
have become very attractive targets for novel cancer 
therapies. TICs share some features with stem cells, and 
many studies have investigated the signaling pathways 
regulating their proliferation, asymmetric cell division and 
migrating properties, as well as their ability to undergo 
proliferation under anchorage-independent conditions [5-
7]. In fact, this latter property is being widely exploited 
to isolate TICs, which are able to survive and clonally 
expand as tumor-spheres, when placed in non-adherent 
settings [8]. Tumor-spheres generated from breast cancer 
cells are known as mammospheres. 
The metabolic requirements of TICs remain a fairly 
unexplored area of investigation. We and others have 
recently shown that TICs rely mainly on mitochondrial 
metabolism, as compared to the more differentiated tumor 
cell population [9-12]. Also, it was previously shown 
that the radio-resistance of TICs from gliomas [13] and 
breast cancers [14] correlates with higher mitochondrial 
respiration. 
We have demonstrated that >60 mitochondrial 
proteins are up-regulated in mammospheres derived from 
breast cancer cell lines (MCF7 and T47D), relative to 
cells grown in monolayers. Furthermore, pharmacological 
inhibition with oligomycin A, an inhibitor of the ATP 
synthase, greatly reduced mammosphere formation [11]. 
More importantly, treatment with doxycycline, an FDA-
approved antibiotic targeting mitochondrial ribosomes as 
a known ‘side effect’, inhibited the formation of tumor-
spheres generated from cell lines across several different 
tumor types, as well as from primary tumor samples [12].
These studies indicate that mitochondria in TICs are 
potentially druggable targets for the prevention of tumor 
recurrence and metastasis. The aim of our current study 
was to further validate mitochondrial function as a critical 
target for the development of new anti-cancer therapies. 
Here, we employed XCT790 as an investigational 
compound to inhibit mitochondrial oxidative 
phosphorylation [15]. XCT790 is a well-established 
inverse agonist of Estrogen-Related Receptor α (ERRα), 
which functions as an essential cofactor of PGC1α. 
Importantly, PGC1α is required for the transcription 
of nuclear-encoded mitochondrial genes and drives 
mitochondrial biogenesis [16, 17]. XCT790 has been 
shown to inhibit colony formation in soft agar induced by 
PGC1α [18], and to induce cell death in chemo-resistant 
cancer cells [19]. However, to our knowledge, no studies 
have previously investigated the effects of XCT790 on the 
propagation and survival of TICs.
Here, our results show that XCT790 inhibits the 
proliferation of TICs from MCF7 breast cancer cells, 
as assessed using i) mammosphere formation and by 
ii) CD44/CD24 immuno-staining, coupled with FACS 
analysis. We also demonstrate that XCT790 suppresses 
the activation of well-established pathways governing 
TIC proliferation and survival, including Sonic hedgehog, 
TGFβ-SMAD, STAT3, and Wnt signaling. As expected, 
XCT790 profoundly reduced mitochondrial respiration. 
Importantly, XCT790-induced TIC inhibition could be 
rescued by treatment with Acetyl-L-Carnitine (ALCAR), 
a mitochondrial fuel and cofactor, which enhances 
mitochondrial oxidative metabolism and biogenesis [20]. 
We also show that overexpression of ERRα is sufficient 
to augment MCF7 cell mammosphere formation, which 
can be blocked by treatment with mitochondrial inhibitors, 
such as XCT790 and oligomycin A, an inhibitor of ATP 
synthase. Finally, we show that mammosphere formation 
driven by FOXM1, a transcription factor downstream of 
Wnt/β-catening signaling that governs stemness [21-24], 
can also be blocked by treatment with three different 
classes of mitochondrial inhibitors (XCT790, oligomycin 
A, or doxycycline). 
Thus, our results firmly establish that mitochondrial 
biogenesis and metabolism are required for the survival 
of TICs, indicating that mitochondrial-targeted therapies 
are a promising novel strategy for targeting TICs for the 
treatment of relapsed and resistant cancers. Mitochondrial-
targeted therapies should also be considered for cancer 
prevention. 
RESULTS
Mammosphere formation in MCF7 cells depends 
on mitochondrial function
We have previously shown that mitochondrial 
proteins are up-regulated in mammospheres derived from 
breast cancer cell lines (MCF7 and T47D), relative to cells 
grown in monolayers [11]. Furthermore, pharmacological 
inhibition with oligomycin A, an inhibitor of ATP 
synthase, greatly reduced mammosphere formation [11]. 
More importantly, treatment with doxycycline, an FDA-
approved antibiotic that targets mitochondrial ribosomes 
as a known ‘side effect’, inhibited the formation of tumor-
spheres derived from 12 cell lines across eight different 
tumor types, as well as from primary tumor samples [12].
To further investigate the role of mitochondria 
in TICs, here we employed a well-established inverse 
agonist of ERRα, namely XCT790. ERRα is a cofactor 
of PGC1α/β, which is required for the transcription 
of nuclear mitochondrial genes and mitochondrial 
biogenesis [16, 17]. As such, XCT790 is believed to 
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suppress mitochondrial function. Notably, treatment with 
XCT790 dose-dependently inhibits MCF7 mammosphere 
formation, with an IC-50 of 10 μM (Figure 1A). We also 
validated that XCT790 dose-dependently reduces the 
protein expression of PGC1α in MCF7 cell monolayers 
by immuno-blot analysis (data not shown), by up to 70-
80%, over this concentration range. 
These results were independently confirmed by 
evaluating the expression of bona-fide TIC markers CD44/
CD24 by FACS. Under these conditions, CD44(+)high/
CD24(-)low cells are considered to represent the TIC 
sub-population. XCT790 treatment significantly reduced 
the number of CD44(+)high/CD24(-)low cells in a dose-
dependent fashion, relative to vehicle alone controls 
(Figure 1B). 
We next set out to investigate if XCT790 can target 
TICs in the presence of the total cancer cell population. To 
this end, MCF7 cells were treated with XCT790 (at 5 or 10 
µM) as monolayers for 2 days and then re-plated on low-
attachment plates in the absence of XCT790, to generate 
mammospheres for 5 days. Under these conditions, 
XCT790 pre-treatment dose-dependently reduced MCF7 
cell mammosphere formation, by up to ~70% (Figure 1C), 
indicating that XCT790 can target the TIC population also 
Figure 1: MCF7 cell 3D-spheroid formation depends on mitochondrial function. A. The well-established ERRα inverse 
agonist, namely XCT790, dose-dependently inhibits MCF7 mammosphere formation, with an IC-50 of 10 μM. ERRα is a cofactor of 
PGC1α, which is required for the transcription of mitochondrial genes and mitochondrial biogenesis. *p < 0.01 evaluated by Student’s t test. 
B. MCF7 cells were pre-treated with XCT790 (at 5 or 10 μM) as monolayers for 2 days and then re-plated on low-attachment plates in the 
absence of XCT790, for anoikis assay for 10 hours. Expression of TIC markers CD24 and CD44 was analyzed by FACS. Note that XCT790 
pre-treatment dose-dependently reduced the number of CD44(+)high/CD24(-)low cells, which are considered the TICs population. ****p 
< 0.00001 evaluated with one-way ANOVA. C. MCF7 cells were pre-treated with XCT790 (at 5 or 10 μM) as monolayers for 2 days and 
then re-plated on low-attachment plates in the absence of XCT790, for mammosphere assay for 5 days. Under these conditions, XCT790 
pre-treatment dose-dependently reduced MCF7 cell mammosphere formation, by up to ~70%. **p < 0.001 and ****p < 0.00001 evaluated 
with one-way ANOVA. D. Treatment with the mitochondrial cofactor Acetyl L-Carnitine (ALCAR) rescues the decreased mammosphere 
formation induced by XCT790. Mammosphere formation was assessed upon treatment with 20 μM XCT790 and increasing concentration 
of ALCAR. Thus, mitochondrial function is required for the efficient clonal expansion and anchorage-independent growth of TICs. *p 
< 0.05; **p < 0.001, relative to XCT790 only treated cells (0μM ALCAR) evaluated by Student’s t test. MFE: mammosphere forming 
efficiency.
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when present in a heterogeneous cell population. 
Also, we asked if decreased mammosphere 
formation induced by XCT790 could be rescued by 
treatment with the mitochondrial cofactor Acetyl-
L-Carnitine (ALCAR). ALCAR plays a key role in 
mitochondrial oxidative metabolism, by enhancing fatty 
acid β-oxidation [20]. ALCAR stimulates mitochondrial 
biogenesis and is also directly converted to acetyl-CoA, 
a mitochondrial fuel [20]. To this end, mammosphere 
formation was assessed after treatment with XCT790 
(at 20 µM) and increasing concentrations of ALCAR. 
Figure 1D shows that ALCAR rescues the decrease 
in mammosphere formation induced by XCT790, in a 
dose-dependent manner. Thus, mitochondrial function is 
required for the efficient clonal expansion and anchorage-
independent growth of TICs. 
We then examined if XCT790 affects the viability of 
the total cancer cell population, or if it specifically inhibits 
the viability of MCF7 cells in mammospheres. To this end, 
MCF7 cells were treated with increasing concentrations 
of XCT790 as monolayers for 3 days (Figure 2A) or 5 
days (Figure 2B). Cell viability was then assessed using 
the SRB assay. Note that 5-day treatment did not affect 
the viability of the MCF7 cell monolayers, as profoundly 
as MCF7 cell mammospheres (Figure 2B). For example, 
treatment with 10 µM XCT790 reduces mammosphere 
formation by 50% (Figure 1A), whereas the viability 
of monolayer cells is reduced by only 20%. Thus, 
XCT790 preferentially reduces the viability of MCF7 cell 
mammospheres, relative to bulk cancer cells.
XCT790 inhibits the activation of several stem cell 
related signaling pathways
To further corroborate the idea that XCT790 inhibits 
cancer stem cell-like features, we next analyzed the effects 
of XCT790 on a series of well-established signaling 
pathways, which have been shown to promote stemness. 
For this purpose, we employed a panel of eight MCF7 cell 
lines carrying different luciferase reporters [25], to monitor 
the activation state of a variety of different signaling 
networks, including Sonic hedgehog, TGFβ-SMAD, 
STAT3, Wnt, Interferon (IFN)-α/β-STAT1/2, NRF2-
dependent antioxidant responses, IFN-γ-STAT1 and Notch 
pathways. Notably, several pathways were significantly 
inhibited by XCT790 treatment, including stem cell 
signaling (Sonic hedgehog, TGFβ-SMAD, STAT3, Wnt) 
and IFN-α/β-STAT1/2 signaling (Figure 3A). However, no 
effects were observed on the NRF2-antioxidant response, 
IFN-γ-STAT1 and the Notch pathways (Figure 3B). 
Thus, XCT790 inhibits the activation of several signal 
transduction pathways related to cancer stem-like features. 
XCT790 inhibits mitochondrial respiration
Next, we set out to investigate the mechanism(s) by 
which XCT790 inhibits mammosphere formation and CSC 
features. XCT790 is an inverse agonist of ERRα, which 
is a cofactor of PGC1α required for the transcription of 
mitochondrial genes and mitochondrial biogenesis. Thus, 
the metabolic profile of MCF7 cells treated with XCT790 
was analyzed. To this end, MCF7 cells were treated with 
XCT790 for 48 hours, stained with various MitoTracker 
Figure 2: XCT790 preferentially reduces the viability of MCF7 cells in mammospheres, relative to bulk cancer cells. 
MCF7 cells were treated with XCT790 (1, 5, 10, 20 μM) as monolayers for 3 days A. or 5 days B. Cell viability was assessed by SRB 
assay. Note that 5-day treatment did not affect the viability of the MCF7 cell monolayers as profoundly as MCF7 cell mammospheres. For 
example, treatment with 10 μM XCT790 reduces mammosphere formation by 50% (Figure 1A), whereas viability of monolayer cells is 
reduced by 20%. **p < 0.01; ***p < 0.001 evaluated by Student’s t test.
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Figure 3: XCT790 inhibits signaling pathways related to cancer stem cells, and interferon. MCF7 breast cancer cells 
carrying luciferase-reporters (Cignal, QIAGEN) were generated to monitor the activation of a variety of signaling networks, including 
Sonic hedgehog TGFβ-SMAD, STAT3, Wnt, Interferon (IFN)-α/β-STAT1/2, NRF2-dependent antioxidant responses, IFN-γ-STAT1 and 
Notch pathways. MCF7-Luc reporter cells were treated with XCT790 for 48 hours and luminescence was determined as a measure of 
pathway activation status. Luminescence was normalized by protein content. A. Note that XCT790 inhibits cancer stem cell signaling (Sonic 
hedgehog TGFβ-SMAD, STAT3, Wnt), as well as IFN-α/β-STAT1/2 signaling. B. No effects were observed for the NRF2-antioxidant 
responses, IFN-γ-STAT1 and Notch pathways. *p < 0.01; **p < 0.001; ***p < 0.0001, using Student’s t test.
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probes and analyzed by FACS. Figure 4A shows that 
XCT790 induces a decrease in mitochondrial membrane 
potential, as assessed with MitoTracker Orange, which 
accumulates in mitochondria with an active mitochondrial 
potential. Surprisingly, XCT790 induces also an increase 
in mitochondrial mass, as assessed with MitoTracker 
Green (Figure 4B), localizing to mitochondria regardless 
of mitochondrial membrane potential. Similar results 
were obtained with MitoTracker Deep Red, which also 
measures mitochondria mass (data not shown). Analysis 
of the ratio of mitochondrial membrane potential versus 
mitochondrial mass indicates that XCT790 induces a 
profound decrease in mitochondrial membrane potential 
per mitochondria (Figure 4C).
Also, the metabolic profile of MCF7 cells treated 
with XCT790 was examined using the Seahorse XFe96 
analyzer, by employing a mitochondrial stress test. 
Notably, the oxygen consumption rate (OCR) was greatly 
reduced by treatment with XCT790 (Figure 5A). Further 
quantification revealed significant reductions in basal and 
maximal respiration (Figure 5B-5C), as well as ATP levels 
(Figure 5D), upon XCT790 treatment. Thus, XCT790 
significantly reduces the rates of oxidative mitochondrial 
metabolism. To further validate these results, a glycolytic 
stress test was performed using the Seahorse XFe96 
analyzer, by measuring the extracellular acidification rate 
(ECAR) of MCF7 cells treated with XCT790. Notably, 
XCT790 also significantly reduces ECAR, a marker of 
glycolysis (Figure 6A). Finally, plotting the ratio of OCR 
to ECAR demonstrates that XCT790 shifts MCF7 cells 
from a highly energetic to a metabolically quiescent state 
(Figure 6B).
ERRα expression is both necessary and sufficient 
to increase mammosphere formation in MCF7 
cells
XCT790 is an inverse agonist of ERRα. As XCT790 
inhibits mammosphere formation, we then asked if ERRα 
expression is sufficient to promote 3D-spheroid formation 
in MCF7 cells. To this end, ERRα was over-expressed 
in MCF7 cells using a lentiviral approach. Empty Vector 
(EV) cells were generated in parallel. Figure 7A shows that 
MCF7 cells over-expressing ERRα show a 50% increase 
in mammosphere forming capacity. Notably, MCF7 cells 
over-expressing ERRα show increased mitochondrial 
membrane potential, as assessed by MitoTracker Orange, 
as well as increased mitochondrial mass, as assessed 
by MitoTracker Green and MitoTracker Deep Red, as 
expected (Figure 7B). 
We then used a pharmacological approach to inhibit 
ERRα-driven mammosphere formation, using oligomycin 
A, a mitochondrial inhibitor, as well as XCT790, a specific 
ERRα inverse agonist. Importantly, mammosphere 
formation induced by ERRα expression was inhibited 
by either treatment with oligomycin A (Figure 7C), or 
XCT790 (Figure 7D). These results indicate that ERRα 
activity and mitochondrial function are normally required 
for the clonal expansion of TICs. 
Mammosphere formation driven by FOXM1 
requires mitochondrial function
To examine if mitochondrial function is essential 
for TIC expansion driven by well-established stem-
like signaling, we decided to overexpress FOXM1 in 
Figure 4: XCT790 induces a decrease in mitochondrial membrane potential, with an unexpected increase in 
mitochondrial mass. MCF7 cells were treated with XCT790 (10 μM) as monolayers for 48 hours, stained with various MitoTracker 
probes and analyzed by FACS. A. XCT790 induces a decrease in mitochondrial membrane potential, as assessed with MitoTracker Orange, 
which accumulates in mitochondria with an active mitochondrial potential. B. XCT790 induces an unexpected increase in mitochondrial 
mass, as assessed with MitoTracker Green, which localizes to mitochondria regardless of mitochondrial membrane potential. C. Ratio of 
mitochondrial membrane potential (MitoTracker Orange), versus mitochondrial mass (MitoTracker Green) demonstrates that XCT790 
induces a large decrease in mitochondrial membrane potential per mitochondria. ****p < 0.00001 evaluated with Student’s t test. 
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Figure 6: XCT790 shifts MCF7 cells from a highly energetic to a metabolically quiescent state. A. Extracellular acidification 
rate (ECAR) of MCF7 cell monolayers treated with XCT790 (10 μM) for 2-days was assessed using the Seahorse XFe96 analyzer. Note 
that XCT790 significantly reduces ECAR, a marker of glycolysis. *p < 0.01 evaluated with Student’s t test. B. OCR plotted against ECAR. 
Note that MCF7 cells treated with XCT790 were shifted towards a more metabolically quiescent state. 
Figure 5: XCT790 quantitatively reduces mitochondrial respiration. The metabolic profile of MCF7 cell monolayers treated 
with XCT790 (5 or 10 μM) for 2-days was examined using the Seahorse XFe96 analyzer. A. Oxygen consumption rate (OCR) is significantly 
reduced by treatment with 10 μM XCT790. B., C., D. Significant reductions in respiration (basal and maximal) and in ATP levels were 
observed upon XCT790 treatment. Thus, the rates of oxidative mitochondrial metabolism were significantly reduced by XCT790 treatment. 
***p < 0.0001, ****p < 0.00001 evaluated with one-way ANOVA. 
Oncotarget14784www.impactjournals.com/oncotarget
Figure 7: ERRα expression is required for 3D-spheroid formation in MCF7 cells. ERRα was over-expressed in MCF7 
cells using a lentiviral approach. Empty Vector (EV) cells were generated in parallel. A. MCF7 cells overexpressing ERRα show a 
50% increase in mammosphere forming capacity, relative to EV controls. B. MCF7 cells over-expressing ERRα show an increase of 
mitochondrial membrane potential, as assessed by MitoTracker Orange staining, as well as an increase in mitochondrial mass, as assessed 
by MitoTracker Green and MitoTracker Deep Red staining, as expected. C. Oligomycin A, an inhibitor of mitochondrial ATP synthase, 
inhibits mammosphere formation in MCF7 cells overexpressing ERRα, indicating that mitochondrial function is required for ERRα-driven 
mammosphere formation. D. XCT790, an ERRα inverse agonist, inhibits mammosphere formation in MCF7 cells over-expressing ERRα. 
Thus, ERRα activity is required for the efficient clonal expansion of TICs. EV: Empty Vector. *p < 0.05, **p < 0.01, ***p < 0.001 evaluated 
by Student’s t test. 
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MCF7 cells. Empty Vector (EV) control cells were 
generated in parallel. The transcription factor FOXM1 
was recently shown to induce the expansion of human 
normal stem cells, as well as of cancer stem-like cells 
[21-24]. Mechanistically, it is believed that FOXM1 acts 
downstream of key signaling pathways essential for stem 
cell regulation and tumorigenesis, such as Wnt/β-catenin 
and 14-3-3ζ signaling cells [22, 26].
MCF7 cells over-expressing FOXM1 show a 3.3-
fold increase in mammosphere formation, relative to 
empty-vector controls, as expected (Figure 8A). In order 
to better dissect the molecular changes driven by FOXM1, 
MCF7 cell monolayers over-expressing FOXM1 and 
EV control cells were subjected to proteomics analysis. 
Proteomic datasets of up-regulated proteins in the MCF7-
FOXM1 cells were then analyzed with respect to their 
metabolic protein profiles. 
Table 1 shows that several key molecules related to 
mitochondria, glycolysis and the EMT are up-regulated 
in FOXM1-over-expressing MCF7 cells, indicating that 
FOXM1-induced stemness is associated with increased 
metabolic flexibility. Notably, keratin-19 (KRT19), a 
well-established marker of circulating tumor cells and 
CSCs, is increased by >20-fold in MCF7-FOXM1 cells. 
Also, four key mitochondrial proteins (HSPD1, ACADVL, 
ATP5B, COX4I1) are increased by >10-fold each in 
MCF7-FOXM1 cells; SLC25A4 (the mitochondrial ATP/
ADP exchanger) is increased by nearly 6-fold. Similarly, 
twenty-two other mitochondrial proteins are increased by 
>1.5 fold. 
Moreover, Table 2 shows that several key molecules 
related to protein synthesis are also up-regulated in 
FOXM1-overexpressing MCF7 cells. We have previously 
shown that protein synthesis is a mechanism for enhancing 
the proliferation of TICs, and that known inhibitors of 
protein synthesis, such as puromycin and rapamycin, are 
very effective at reducing mammosphere formation [27]. 
Similarly, the EMT is also regarded as a key feature of 
TICs [28, 29]. Consistent with the notion that FOXM1 
drives stemness, ribosome-related proteins and EMT 
markers are increased by FOXM1 expression (Tables 1 
and 2).
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To test if mitochondrial inhibitors could block 
FOXM1-driven mammosphere formation, we then 
used several independent pharmacological approaches. 
Interestingly, formation of FOXM1-driven mammospheres 
was inhibited by treatment with oligomycin A (Figure 
8B), XCT790 (Figure 8C), and doxycycline (Figure 
8D). Doxycycline is an FDA-approved antibiotic that 
we have recently shown to inhibit proliferation of TICs, 
by targeting their mitochondrial ribosomes [12]. Thus, 
mitochondrial protein translation and function are required 
for FOXM1-driven mammosphere formation. 
Mitochondrial function is required for 
3D-spheroid formation using H295R cells
Finally, we asked if mitochondrial function 
is required for 3D-spheroid formation of other cell 
lines, such as H295R adrenocortical carcinoma cells. 
Figure 9 shows that XCT790 dose-dependently inhibits 
3D-spheroid formation of the H295R adrenocortical 
carcinoma cell line, with an IC-50 of 10 μM. These results 
indicate that mitochondrial function is required for the 
3D-spheroid formation of cell lines other than MCF7 
breast cancer cells.
Quantitatively similar results were obtained when 
XCT790 was tested on several other epithelial cancer 
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Figure 8: Mammosphere formation driven by FOXM1 requires mitochondrial function. FOXM1 was over-expressed 
in MCF7 cells using a lentiviral approach. Empty Vector (EV) cells were generated in parallel. A. MCF7 cells over-expressing FOXM1 
show a >3.3-fold increase in mammosphere formation. B. Treatment with oligomycin A, an inhibitor of the mitochondrial ATP synthase, 
inhibits mammosphere formation in MCF7 cells over-expressing FOXM1. C. Treatment with XCT790 inhibits mammosphere formation in 
MCF7 cells over-expressing FOXM1. D. Treatment with doxycycline, an FDA-approved antibiotic that we have recently shown to inhibit 
proliferation of TICs by targeting TIC mitochondria, inhibits mammosphere formation in MCF7 cells over-expressing FOXM1. Thus, 
mitochondrial function is required for FOXM1-driven mammosphere formation. EV: Empty Vector. *p < 0.05, **p < 0.01, ***p < 0.001 
evaluated by Student’s t test. 
Figure 9: 3D-spheroid formation in H295R cells is dependent upon mitochondrial function. XCT790 dose-dependently 
inhibits 3D-spheroid formation in H295R cells, an adrenocortical carcinoma cell line, with an IC-50 of 10 μM. These results indicate that 
mitochondrial function is required for the 3D-spheroid formation in cell lines other than MCF7 breast cancer cells. TSFE, tumor-sphere 
forming efficiency; *p < 0.05 evaluated by Student’s t test.
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cell lines, indicating that the ability of XCT790 to inhibit 
3D-spherioid formation reflects a general property of 
CSCs (data not shown). 
Relevance of FOXM1-related targets in human 
breast cancers
To assess the possible clinical relevance of our 
results, we also determined whether the proteomic 
targets that we identified in MCF7-FOXM1 cells were 
transcriptionally over-expressed in human breast cancer 
cells in vivo. Towards this end, we exploited a clinical data 
set of tumor samples from 28 breast cancer patients. These 
tumor samples were subjected to laser-capture micro-
dissection, to separate epithelial cancer cells from adjacent 
tumor stroma [30].
Tables 3 and 4 present a summary of these findings. 
Overall, greater than fifty FOXM1 targets (related to 
mitochondria, glycolysis, the EMT, and protein synthesis) 
that we identified in MCF7-FOXM1 cells were also 
transcriptionally elevated in human breast cancer cells 
in vivo. As such, the new FOXM1 protein targets that 
we identified in MCF7-FOXM1 cells may be especially 
relevant for improving human breast cancer diagnosis and 
therapy. 
DISCUSSION
Here, we specifically tested the hypothesis that new 
mitochondrial biogenesis is required for the survival and 
propagation of stem-like cancer cells. For this purpose, we 
used an investigational inhibitor of the ERRα-PGC1α/β 
signaling pathway, namely XCT790, to interrogate the role 
of mitochondrial biogenesis and function in the anchorage-
independent growth of CSCs. Importantly, treatment with 
XCT790 blocked mammosphere formation and prevented 
anoikis-resistance in CD44(+)high/CD24(-)low MCF7 
cells. Mechanistically, XCT790 inhibited mitochondrial 
function (OCR) and effectively reduced signaling along 
a number of classical stem cell transduction pathways, 
such as the Hedgehog/GLI, TGFβ/SMAD, and Wnt/β-
catenin signaling. Overexpression of either ERRα or 
FOXM1 (a down-stream target of Wnt-signaling [22]) 
in MCF7 cells significantly augmented mammosphere 
formation, which could be prevented by a number of 
mitochondrial inhibitors. In this regard, doxycycline 
treatment was sufficient to overcome the effects of 
FOXM1 on mammosphere formation. Interestingly, 
doxycycline is an FDA-approved antibiotic that has 
been used for nearly 50 years to treat a wide variety of 
bacterial and parasitic infections, without significant 
side effects. Finally, unbiased proteomics analysis of 
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MCF7-FOXM1 cells revealed the up-regulation of 
specific mitochondrial proteins, glycolytic enzymes, 
EMT markers and components of the protein synthesis 
machinery. Importantly, these FOXM1 target proteins 
were also transcriptionally up-regulated in patient samples 
in vivo, in human breast cancer epithelial cells isolated by 
laser-capture micro-dissection, highlighting their clinical 
relevance. 
Many other recent studies have also directly 
implicated augmented mitochondrial function in resistance 
to chemotherapy and radiation [31-36], in the survival 
of treatment-resistant cancer stem-like cells [37], in the 
propagation and motility of circulating tumor cells [38], 
as well as in tumor growth and cancer cell metastasis in 
pre-clinical animal models in vivo [39-44]. 
Consistent with our current findings, we have 
previously shown that a PGC1/NRF1 gene signature 
predicts tumor recurrence, metastasis and poor overall 
survival in ER(+)/Luminal-A breast cancer patients [45]. 
This PGC1/NRF1 gene signature was also elevated in 
>2,000 human tumors excised from breast cancer patients, 
including both ER(+)and ER(-) cases [45]. Moreover, 
recombinant over-expression of PGC1α/β, or other genes 
that promote mitochondrial biogenesis (MitoNEET/
POLRMT), in MDA-MB-231 cells, was indeed sufficient 
to functionally increase tumor growth by up to ~3-fold 
[43]. 
Asymmetric cell division is an essential 
characteristic of stem cells. Interestingly, Sabatini, 
Weinberg and colleagues examined the segregation 
of “newly-synthesized” and “older” mitochondria 
in immortalized mammary epithelial cells, during 
asymmetric cell division, a property that is also a 
characteristic of CSCs [46]. They observed that “newly-
synthesized” mitochondria were preferentially enriched in 
stem cells during asymmetric cell division, while “old” 
mitochondria were segregated into the daughter cells [46]. 
These results imply that asymmetric cell division in stem 
cells somehow requires new mitochondrial biogenesis, 
for the propagation and maintenance of the stem cell 
phenotype. 
As such, these findings may help to mechanistically 
explain our current results that new mitochondrial 
biogenesis is required for the efficient propagation of and 
Figure 10: Understanding the role of mitochondrial biogenesis and function in the propagation of CSCs/TICs. ERRα 
is a co-factor for PGC1α/β, which is a well-established transcription factor that is critical for driving new mitochondrial biogenesis. Here, 
we show that three different classes of mitochondrial inhibitors (XCT790, oligomycin A and doxycycline) all prevent the propagation of 
CSCs/TICs. XCT790 is an inverse agonist of ERRα. Oligomycin A is an inhibitor of the mitochondrial ATP-synthase (complex V) (not 
shown). Finally, doxycycline is an inhibitor of mitochondrial protein synthesis, as it binds directly to the small subunit of the mitochondrial 
ribosome. This reflects the fact that mitochondria were originally derived from aerobic bacteria that evolved over millions of years, to 
establish a symbiotic relationship with the host cell. The chemical structures of XCT790 and doxycycline are also shown. 
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survival of CSCs (Figure 10), as we have seen using the 
mammosphere and anoikis-resistance assays, to measure 
stem cell activity. Taken together, these data implicate 
mitochondrial biogenesis and mitochondrial function 
as critical targets for new drug discovery, to overcome 
tumor recurrence, distant metastasis and drug-resistance, 
especially in cancer patients with clinically advanced 
disease. 
MATERIALS AND METHODS
Materials
MCF7 breast cancer cells were purchased from 
the ATCC. H295R adrenocortical carcinoma cells were 
a generous gift of Dr. Antonio Stigliano (University of 
Rome). Gibco-brand cell culture media (DMEM/F12) 
was purchased from Life Technologies. XCT790 was 
purchased from Tocris, oligomycin A and doxycycline 
were purchased from Sigma-Aldrich. Lentiviral vectors 
for the expression of ERRα (#Z1441) and FOXM1 
(#U1376) were obtained commercially from Genecopoeia, 
along with the appropriate empty vector controls, in the 
Lv-105 (PuroR) vector system. 
Mammosphere culture
A single cell suspension was prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle) to create 
a single cell suspension [8]. Cells were plated at a 
density of 500 cells/cm2 in mammosphere medium 
(DMEM-F12/ B27/ EGF(20ng/ml)/ Pen-Strep) in non-
adherent conditions, in culture dishes coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932). Cells were grown for 5 days and maintained 
in a humidified incubator at 37°C at an atmospheric 
pressure in 5% (v/v) carbon dioxide/air. After 5 days for 
culture, spheres >50 μm were counted using an eye piece 
graticule, and the percentage of cells plated which formed 
spheres was calculated and is referred to as percentage 
mammosphere formation, and was normalized to one (1 
= 100 %MSE, mammosphere forming efficiency). For 
pharmacological inhibition of mammosphere formation, 
cells were directly seeded on low-attachment plates in the 
presence of XCT790 or oligomycin or doxycycline at the 
indicated concentrations. 
Pre-treatment of monolayers with XCT790
After incubation with XCT790 (5 or 10 μM for 
48 hours), MCF7 cell monolayers were trypsinized and 
seeded for mammosphere cultures for 5 days, without 
XCT790. 
Lentiviruses
Lentiviral plasmids, packaging cells and reagents 
were from Genecopoeia. 48 hours after seeding, 293Ta 
packaging cells were transfected with lentiviral vectors 
encoding ERRα, FOXM1 or empty vector (EX-NEG-
Lv105), using Lenti-PacTM HIV Expression Packaging 
Kit according to the manufacturer’s instructions. Two days 
post-transfection, lentivirus-containing culture medium 
was passed through a 0.45 µm filter and added to the target 
cells (MCF7 cells) in the presence of 5µg/ml Polybrene. 
Infected cells were selected with a concentration of 1.5 µg/
ml of puromycin.
CD44/CD24 analysis
Following XCT790 treatment for 48 hours, the TIC 
population was enriched by seeding on low-attachment 
plates. Under these conditions, the non-TIC population 
undergoes anoikis (a form of apoptosis induced by a 
lack of cell-substrate attachment) and TICs are believed 
to survive. The surviving TIC fraction was analyzed by 
FACS analysis. Briefly, 1 x 104 MCF7 monolayer cells 
were treated with XCT790 (5μM and 10 μM) for 48h in 
6-well plates. Then, cells were trypsinized and seeded in 
low-attachment plates in mammosphere media. After 10h, 
MCF7 cells were spun down and incubated with CD24 
(IOTest CD24-PE, Beckman Coulter) and CD44 (APC 
mouse Anti-Human CD44, BD Pharmingen cat.559942) 
antibodies for 15 minutes on ice. Cells were rinsed twice 
and incubated with LIVE/DEAD dye (Fixable Dead Violet 
reactive dye; Invitrogen) for 10 minutes. Samples were 
then analyzed by FACS (Fortessa, BD Bioscence). Only 
the live population, as identified by the LIVE/DEAD dye 
staining, was analyzed for CD24/CD44 expression. Data 
were analyzed using FlowJo software. 
Viability assay
Cell viability was assessed by sulphorhodamine 
(SRB) assay, based on the measurement of cellular protein 
content. After treatment with XCT790 for 3 or 5 days in 
96 well plates, cells were fixed with 10% trichloroacetic 
acid (TCA) for 1h in cold room, and dried overnight at 
room temperature. Then, cells were incubated with SRB 
for 15 min, washed twice with 1% acetic acid, and air 
dried for at least 1h. Finally, the protein-bound dye was 
dissolved in 10 mM Tris pH 8.8 solution and read using 
the plate reader at 540 nm.
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Evaluation of CSC signalling pathways
The Cignal Lenti reporter assay (luc) system 
(Qiagen) was chosen for monitoring the activity of several 
signaling pathways in MCF7 cells [25]. The responsive 
luciferase constructs encode the firefly luciferase reporter 
gene under the control of a minimal (m)CMV promoter 
and tandem repeats of response elements for each pathway. 
The following constructs were used: TCF/LEF(luc) for 
Wnt signaling (CLS-018L); STAT3(luc) for transcriptional 
activity of STAT3 (CLS-6028L); RBP-Jk(luc) for Notch-
induced signaling (CLS-014L); ARE(luc) for Nrf2- and 
Nrf1-mediated antioxidant response (CLS-2020L); 
GAS(luc) for IFNγ-induced Stat1-signaling (CLS-009L); 
ISRE(luc) for (IFN)-α/β-STAT1/2 signaling (CLS-008L); 
SMAD(luc) for TGFβ-induced signaling (CLS-017L); 
GLI(luc) for Sonic hedgehog signaling (CCS-6030L). 
Briefly, 1 x 105 MCF7 cells were seeded in 12-well plates. 
Once cells were attached, the viral particles were diluted 
1:10 in complete culture media containing polybrene (sc-
134220, Santa Cruz), and added to the cells. Puromycin 
treatment (#P9620, Sigma) was started 48 hours later in 
order to select stably infected cells. 
Luciferase assay
Luciferase Assay System (E1501, Promega) was 
performed in all luciferase reporter MCF7 cells treated 
with XCT790. Briefly, 6 × 103 MCF7 cells were seeded 
in black-walled 96-well plates and then were treated with 
XCT790 (10 μg/ml). As control, vehicle-treated cells 
were run in parallel. Four replicates were used for each 
condition. After 48 hours of treatment, luciferase assay was 
performed according to the manufacturer’s instructions. 
Light signal was acquired for 2 minutes in photons/second 
in the Xenogen VivoVision IVIS Lumina (Caliper Life 
Sciences), and the results were analysed using the Living 
Image 3.2 sofware (Caliper Life Sciences). Luminescence 
was normalized using total proteins, as assessed with the 
Bradford protein assay.
Mitochondrial staining
To measure mitochondrial activity, cells were 
stained with MitoTracker Orange (#M7510, Invitrogen), 
whose accumulation in mitochondria is dependent upon 
membrane potential. To measure mitochondrial mass, 
cells were stained with MitoTracker Green (#M7514 
Invitrogen), or MitoTracker Deep Red (#M22426, 
Invitrogen), both localizing to mitochondria regardless of 
mitochondrial membrane potential. Briefly, MCF7 cells 
were treated with XCT790 for 48 hours. Cells were then 
incubated with pre-warmed MitoTracker staining solution 
(diluted in PBS/CM to a final concentration of 10 nM) for 
30-60 min at 37 °C. All subsequent steps were performed 
in the dark. Cells were washed in PBS, harvested, and re-
suspended in 300 μL of PBS. Cells were then analyzed 
by flow cytometry. Data analysis was performed using 
FlowJo software.
Seahorse XFe96 metabolic flux analysis
 Extracellular acidification rates (ECAR) and real-
time oxygen consumption rates (OCR) for MCF7 cells 
treated with XCT790 or vehicle alone control were 
determined using the Seahorse Extracellular Flux (XF96) 
analyzer (Seahorse Bioscience, MA, USA). MCF7 cells 
were maintained in DMEM supplemented with 10% FBS 
(fetal bovine serum), 2 mM GlutaMAX, and 1% Pen-
Strep. 7,000 cells were seeded per well into XF96-well 
cell culture plates, and incubated overnight at 37°C in a 
5% CO2 humidified atmosphere. After 24h, cells were 
treated with XCT790 (5μM or 10 μM) for 48h. After 
48h of treatment, cells were washed in pre-warmed XF 
assay media (for OCR measurement, XF assay media 
was supplemented with 10mM glucose, 1mM Pyruvate, 
2mM L-glutamine and adjusted at pH 7.4). Cells were then 
maintained in 175 µL/well of XF assay media at 37°C, in 
a non-CO2 incubator for 1h. During the cell incubation 
time, we loaded 25 µL each of 80mM glucose, 9µM 
oligomycin, 1M 2-deoxyglucose (for ECAR measurement) 
and 25 µL each of 10µM oligomycin, 9µM FCCP, 10µM 
rotenone, 10µM antimycin A (for OCR measurement), 
in XF assay media into the injection ports in the XFe-96 
sensor cartridge. ECAR and OCR measurements were 
normalized by protein content. Data set was analyzed by 
XFe-96 software and GraphPad Prism software, using 
one-way ANOVA and Student’s t-test calculations. All 
experiments were performed in quintuplicate, three times 
independently, such that each data point represents the 
average of 15 replicates.
Label-free quantitative proteomics analysis
Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS [47]. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLCnano system (Thermo Scientific, 
formerly Dionex, The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp., 
Milford, MA, formerly Non-linear dynamics, Newcastle 
upon Tyne, UK) for peak detection and alignment. Data 
were analyzed using the Mascot search engine. Five 
replicates were analyzed for each sample type (N = 5). 
Statistical analyses were performed using ANOVA and 
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only fold-changes in proteins with a p-value less than 0.05 
were considered significant. 
Data mining
To firmly establish the clinical relevance of our 
results from the quantitative proteomics analysis of 
mammosheres, we re-analyzed the transcriptional profiles 
of epithelial breast cancer cells and adjacent tumor 
stromal cells that were physically separated by laser-
capture microdissection (from N = 28 human breast cancer 
patients) [30].
ACKNOWLEDGMENTS
We thank the University of Manchester for providing 
start-up funds that contributed to the success of this study. 
FS and MPL were supported, in part, by funding from the 
European Union (ERC Advanced Grant), Breakthrough 
Breast Cancer, and the Manchester Cancer Research 
Centre (MCRC). DLS was core-funded by CRUK. 
ADL was supported by an E.U. grant for post-doctoral 
associates: Unical (POR Calabria FSE 2007-2013. VP was 
funded by a grant from the Associazione Italiana per la 
Ricerca sul Cancro (AIRC), project n. IG14433.
CONFLICTS OF INTEREST
There is no conflict of interest.
REFERENCES
1. Sinha N, Mukhopadhyay S, Das DN, Panda PK and 
Bhutia SK. Relevance of cancer initiating/stem cells in 
carcinogenesis and therapy resistance in oral cancer. Oral 
oncology. 2013; 49:854-862.
2. Scopelliti A, Cammareri P, Catalano V, Saladino V, 
Todaro M and Stassi G. Therapeutic implications of Cancer 
Initiating Cells. Expert opinion on biological therapy. 2009; 
9:1005-1016.
3. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu 
Y and Tan W. Multi-drug-resistant cells enriched from 
chronic myeloid leukemia cells by Doxorubicin possess 
tumor-initiating-cell properties. Journal of pharmacological 
sciences. 2013; 122:299-304.
4. Easwaran H, Tsai HC and Baylin SB. Cancer epigenetics: 
tumor heterogeneity, plasticity of stem-like states, and drug 
resistance. Molecular cell. 2014; 54:716-727.
5. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn 
M, Yang SX and Ivy SP. Targeting Notch, Hedgehog, and 
Wnt pathways in cancer stem cells: clinical update. Nature 
reviews Clinical oncology. 2015.
6. Angeloni V, Tiberio P, Appierto V and Daidone MG. 
Implications of stemness-related signaling pathways in 
breast cancer response to therapy. Seminars in cancer 
biology. 2015; 31:43-51.
7. Maccalli C and De Maria R. Cancer stem cells: 
perspectives for therapeutic targeting. Cancer immunology, 
immunotherapy : CII. 2015; 64:91-97.
8. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, 
Farnie G and Clarke RB. A detailed mammosphere assay 
protocol for the quantification of breast stem cell activity. 
Journal of mammary gland biology and neoplasia. 2012; 
17:111-117.
9. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, 
Brown D and Mor G. Targeting the mitochondria activates 
two independent cell death pathways in ovarian cancer stem 
cells. Molecular cancer therapeutics. 2011; 10:1385-1393.
10. Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi 
M, Guzzo G, Rasola A, Frasson C, Nardo G, Zulato E, 
Nicoletto MO, Manicone M, Indraccolo S and Amadori A. 
Cancer stem cells from epithelial ovarian cancer patients 
privilege oxidative phosphorylation, and resist glucose 
deprivation. Oncotarget. 2014; 5:4305-4319.
11. Lamb R, Harrison H, Hulit J, Smith DL, Lisanti MP and 
Sotgia F. Mitochondria as new therapeutic targets for 
eradicating cancer stem cells: Quantitative proteomics and 
functional validation via MCT1/2 inhibition. Oncotarget. 
2014; 5:11029-11037.
12. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell 
A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. 
Antibiotics that target mitochondria effectively eradicate 
cancer stem cells, across multiple tumor types: Treating 
cancer like an infectious disease. Oncotarget. 6:4569-4584.
13. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, 
Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian 
C, Reue K, Christofk H, Mischel PS and Pajonk F. 
Metabolic state of glioma stem cells and nontumorigenic 
cells. Proceedings of the National Academy of Sciences of 
the United States of America. 2011; 108:16062-16067.
14. Vlashi E, Lagadec C, Vergnes L, Reue K, Frohnen P, 
Chan M, Alhiyari Y, Dratver MB and Pajonk F. Metabolic 
differences in breast cancer stem cells and differentiated 
progeny. Breast cancer research and treatment. 2014; 
146:525-534.
15. Busch BB, Stevens WC, Jr., Martin R, Ordentlich P, Zhou 
S, Sapp DW, Horlick RA and Mohan R. Identification of 
a selective inverse agonist for the orphan nuclear receptor 
estrogen-related receptor alpha. Journal of medicinal 
chemistry. 2004; 47:5593-5596.
16. Deblois G and Giguere V. Functional and physiological 
genomics of estrogen-related receptors (ERRs) in health and 
disease. Biochimica et biophysica acta. 2011; 1812:1032-
1040.
17. Deblois G, St-Pierre J and Giguere V. The PGC-1/ERR 
signaling axis in cancer. Oncogene. 2013; 32:3483-3490.
18. Fisher KW, Das B, Kortum RL, Chaika OV and Lewis RE. 
Kinase suppressor of ras 1 (KSR1) regulates PGC1alpha 
Oncotarget14794www.impactjournals.com/oncotarget
and estrogen-related receptor alpha to promote oncogenic 
Ras-dependent anchorage-independent growth. Molecular 
and cellular biology. 2011; 31:2453-2461.
19. Wu F, Wang J, Wang Y, Kwok TT, Kong SK and Wong 
C. Estrogen-related receptor alpha (ERRalpha) inverse 
agonist XCT-790 induces cell death in chemotherapeutic 
resistant cancer cells. Chemico-biological interactions. 
2009; 181:236-242.
20. Cassano P, Sciancalepore AG, Pesce V, Fluck M, Hoppeler 
H, Calvani M, Mosconi L, Cantatore P and Gadaleta MN. 
Acetyl-L-carnitine feeding to unloaded rats triggers in 
soleus muscle the coordinated expression of genes involved 
in mitochondrial biogenesis. Biochimica et biophysica acta. 
2006; 1757:1421-1428.
21. Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem 
A, Wan H and Teh MT. Induction of human epithelial stem/
progenitor expansion by FOXM1. Cancer research. 2010; 
70:9515-9526.
22. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, 
Huang H, Xue J, Liu M, Wang Y, Sawaya R, Xie K, Yung 
WK, Medema RH, He X and Huang S. FoxM1 promotes 
beta-catenin nuclear localization and controls Wnt target-
gene expression and glioma tumorigenesis. Cancer cell. 
2011; 20:427-442.
23. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, 
Li Y, Azmi AS, Miele L and Sarkar FH. Over-expression 
of FoxM1 leads to epithelial-mesenchymal transition and 
cancer stem cell phenotype in pancreatic cancer cells. 
Journal of cellular biochemistry. 2011; 112:2296-2306.
24. Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, 
Huang SC, Hsu KF and Chou CY. FOXM1 confers 
to epithelial-mesenchymal transition, stemness and 
chemoresistance in epithelial ovarian carcinoma cells. 
Oncotarget. 2015; 6:2349-2365.
25. Peiris-Pages M, Sotgia F and Lisanti MP. Chemotherapy 
induces the cancer-associated fibroblast phenotype, 
activating paracrine hedgehog-GLI signaling in breast 
cancer cells. Oncotarget. 6:10728-10745.
26. Bergamaschi A, Christensen BL and Katzenellenbogen 
BS. Reversal of endocrine resistance in breast cancer: 
interrelationships among 14-3-3zeta, FOXM1, and a gene 
signature associated with mitosis. Breast cancer research : 
BCR. 2011; 13:R70.
27. Lamb R, Harrison H, Smith DL, Townsend PA, Jackson T, 
Ozsvari B, Martinez-Outschoorn UE, Pestell RG, Howell 
A, Lisanti MP and Sotgia F. Targeting tumor-initiating 
cells: eliminating anabolic cancer stem cells with inhibitors 
of protein synthesis or by mimicking caloric restriction. 
Oncotarget. 2015; 6:4585-4601.
28. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah 
KJ, Bell G, Guo W, Rubin J, Richardson AL and Weinberg 
RA. Paracrine and autocrine signals induce and maintain 
mesenchymal and stem cell states in the breast. Cell. 2011; 
145:926-940.
29. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, Yang J and Weinberg 
RA. The epithelial-mesenchymal transition generates cells 
with properties of stem cells. Cell. 2008; 133:704-715.
30. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, 
Eneman J, Crocker A, White J, Tessitore J, Stanley M, 
Harlow S, Weaver D, Muss H and Plaut K. Molecular 
signatures suggest a major role for stromal cells in 
development of invasive breast cancer. Breast cancer 
research and treatment. 2009; 114:47-62.
31. Bowling BD, Doudican N, Manga P and Orlow SJ. 
Inhibition of mitochondrial protein translation sensitizes 
melanoma cells to arsenic trioxide cytotoxicity via a 
reactive oxygen species dependent mechanism. Cancer 
chemotherapy and pharmacology. 2008; 63:37-43.
32. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, 
Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell 
A, Sotgia F and Lisanti MP. Anti-estrogen resistance in 
breast cancer is induced by the tumor microenvironment 
and can be overcome by inhibiting mitochondrial function 
in epithelial cancer cells. Cancer biology & therapy. 2011; 
12:924-938.
33. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, 
Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, 
Howell A, Pestell RG, Sotgia F and Lisanti MP. Ketones 
and lactate increase cancer cell “stemness,” driving 
recurrence, metastasis and poor clinical outcome in breast 
cancer: achieving personalized medicine via Metabolo-
Genomics. Cell cycle. 2011; 10:1271-1286.
34. Lu CL, Qin L, Liu HC, Candas D, Fan M and Li JJ. Tumor 
cells switch to mitochondrial oxidative phosphorylation 
under radiation via mTOR-mediated hexokinase II 
inhibition--a Warburg-reversing effect. PloS one. 2015; 
10:e0121046.
35. Whitaker-Menezes D, Martinez-Outschoorn UE, 
Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, 
Pavlides S, Tsirigos A, Ertel A, Pestell RG, Broda P, 
Minetti C, Lisanti MP and Sotgia F. Hyperactivation of 
oxidative mitochondrial metabolism in epithelial cancer 
cells in situ: visualizing the therapeutic effects of metformin 
in tumor tissue. Cell cycle. 2011; 10:4047-4064.
36. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia 
F, Lisanti MP and Martinez-Outschoorn UE. Glutamine 
fuels a vicious cycle of autophagy in the tumor stroma and 
oxidative mitochondrial metabolism in epithelial cancer 
cells: implications for preventing chemotherapy resistance. 
Cancer biology & therapy. 2011; 12:1085-1097.
37. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, 
Marchesini M, Carugo A, Green T, Seth S, Giuliani V, 
Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, 
Deem AK, et al. Oncogene ablation-resistant pancreatic 
cancer cells depend on mitochondrial function. Nature. 
2014; 514:628-632.
38. LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman 
Oncotarget14795www.impactjournals.com/oncotarget
H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, 
Domingos Chinen LT, Rocha RM, Asara JM and Kalluri 
R. PGC-1alpha mediates mitochondrial biogenesis and 
oxidative phosphorylation in cancer cells to promote 
metastasis. Nature cell biology. 2014; 16:992-1003, 1001-
1015.
39. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides 
S, Pestell RG, Chiavarina B, Frank PG, Flomenberg 
N, Howell A, Martinez-Outschoorn UE, Sotgia F and 
Lisanti MP. Ketones and lactate “fuel” tumor growth 
and metastasis: Evidence that epithelial cancer cells use 
oxidative mitochondrial metabolism. Cell cycle. 2010; 
9:3506-3514.
40. Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Power 
surge: supporting cells “fuel” cancer cell mitochondria. Cell 
metabolism. 2012; 15:4-5.
41. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio 
M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, 
Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, 
DePinho RA, et al. Glutamine supports pancreatic cancer 
growth through a KRAS-regulated metabolic pathway. 
Nature. 2013; 496:101-105.
42. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya 
B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B, 
Pesdar EA, Sobol M, Filimonenko A, Stuart S, Vondrusova 
M, Kluckova K, et al. Mitochondrial genome acquisition 
restores respiratory function and tumorigenic potential of 
cancer cells without mitochondrial DNA. Cell metabolism. 
2015; 21:81-94.
43. Salem AF, Whitaker-Menezes D, Howell A, Sotgia F and 
Lisanti MP. Mitochondrial biogenesis in epithelial cancer 
cells promotes breast cancer tumor growth and confers 
autophagy resistance. Cell cycle. 2012; 11:4174-4180.
44. Martinez-Outschoorn UE, Sotgia F and Lisanti MP. 
Caveolae and signalling in cancer. Nature reviews Cancer. 
2015; 15:225-237.
45. Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, 
Pavlides S, Martinez-Outschoorn UE, Pestell RG, Howell 
A, Sotgia F and Lisanti MP. Is cancer a metabolic rebellion 
against host aging? In the quest for immortality, tumor 
cells try to save themselves by boosting mitochondrial 
metabolism. Cell Cycle. 2012; 11:253-63. 
46. Katajisto P, Dohla J, Chaffer CL, Pentinmikko N, 
Marjanovic N, Iqbal S, Zoncu R, Chen W, Weinberg RA 
and Sabatini DM. Stem cells. Asymmetric apportioning of 
aged mitochondria between daughter cells is required for 
stemness. Science. 2015; 348:340-343.
47. Holland M, Castro FV, Alexander S, Smith D, Liu J, Walker 
M, Bitton D, Mulryan K, Ashton G, Blaylock M, Bagley S, 
Connolly Y, Bridgeman J, Miller C, Krishnan S, Dempsey 
C, et al. RAC2, AEP, and ICAM1 expression are associated 
with CNS disease in a mouse model of pre-B childhood 
acute lymphoblastic leukemia. Blood. 2011; 118:638-649.
